- Home
- MCRB vs EPSN Comparison
MCRB vs EPSN Comparison
Compare MCRB & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- EPSN
- Stock Information
- Founded
- MCRB 2010
- EPSN 2005
- Country
- MCRB United States
- EPSN Canada
- Employees
- MCRB N/A
- EPSN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- EPSN Oil & Gas Production
- Sector
- MCRB Health Care
- EPSN Energy
- Exchange
- MCRB Nasdaq
- EPSN Nasdaq
- Market Cap
- MCRB 125.7M
- EPSN 124.0M
- IPO Year
- MCRB 2015
- EPSN N/A
- Fundamental
- Price
- MCRB $19.44
- EPSN $6.06
- Analyst Decision
- MCRB Hold
- EPSN Strong Buy
- Analyst Count
- MCRB 4
- EPSN 1
- Target Price
- MCRB $73.67
- EPSN $7.00
- AVG Volume (30 Days)
- MCRB 126.4K
- EPSN 134.8K
- Earning Date
- MCRB 08-06-2025
- EPSN 08-13-2025
- Dividend Yield
- MCRB N/A
- EPSN 4.35%
- EPS Growth
- MCRB N/A
- EPSN N/A
- EPS
- MCRB 10.22
- EPSN 0.23
- Revenue
- MCRB N/A
- EPSN $44,016,087.00
- Revenue This Year
- MCRB N/A
- EPSN $41.35
- Revenue Next Year
- MCRB N/A
- EPSN N/A
- P/E Ratio
- MCRB $1.98
- EPSN $26.19
- Revenue Growth
- MCRB N/A
- EPSN 45.90
- 52 Week Low
- MCRB $6.53
- EPSN $4.95
- 52 Week High
- MCRB $26.40
- EPSN $8.50
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- EPSN 46.24
- Support Level
- MCRB $15.79
- EPSN $5.67
- Resistance Level
- MCRB $18.12
- EPSN $5.89
- Average True Range (ATR)
- MCRB 1.51
- EPSN 0.25
- MACD
- MCRB 0.28
- EPSN 0.02
- Stochastic Oscillator
- MCRB 97.69
- EPSN 62.39
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.